The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.
Tag Archive for: acute myeloid leukemia
After making a splash with the full approval of Eisai and Biogen’s Leqembi (lecanemab) on July 6, the FDA has just three scheduled target action dates coming up in the next two weeks; two for cancer and one for a viral skin disease.
The company halted studies of the treatment for a rare, advanced form of eye cancer after clinical results showed just one response in 47 patients.
The company and partner Seattle Children’s Therapeutics was studying its experimental therapy as a treatment for children with acute myeloid leukemia (AML), a cancer of the blood and bone marrow.
The FDA has placed a partial clinical hold on a Phase I study of Foghorn Therapeutics’ investigational protein degrader FHD-609 after a patient developed a grade 4 QTc prolongation event, the company announced Monday.
Magenta Therapeutics is cutting about 84% of its workforce after a patient’s death halted a Phase I/II trial in acute myeloid leukemia.
Following the death of a patient, Magenta Therapeutics placed a hold on Phase I/II dose-escalation trial of its acute myeloid leukemia therapy.
Following a development setback, MEI Pharma will pivot toward two earlier clinical-stage assets and cut 30% of its workforce in a strategic realignment, the company announced Monday.
The drug will be sold under the brand Rezlidhia and indicated for treating acute myeloid leukemia in patients with a susceptible genetic mutation.